Expression of <i>DNMT3B7</i> in normal and tumor patient samples.

<p>Representative graphs of 6 different tumor samples showing relative <i>DNMT3B7</i> expression, as measured by reads per kilobase per million (RPKM) or RNA-Seq by Expectation Maximization (RSEM), in unmatched normal and tumor tissues in (A) HNSC, (B) UCEC, and (C) THCA. Expression of <i>DNMT3B7</i> in matched patient samples is shown in (D) LIHC and (E) LUAD. <i>DNMT3B7</i> expression in primary and recurrent tissues in (F) LGG (<i>p</i> = 0.005) was assessed when normal samples were not available. All samples shown here were significant, <i>p</i> < 0.001, unless otherwise stated.</p

Relative <i>DNMT3B7</i> expression correlates to clinical staging.

<p><i>DNMT3B7</i> expression was compared to clinical stage and shown to be significantly different in (A) ESCA, <i>p</i> = 0.012; (B) KIRC, <i>p</i> = 0.010; (C) KIRP, <i>p</i> = 0.02; (D) LUSC, <i>p</i> = 0.003; (E) TGCT, <i>p</i><0.001; and (F) LAML, <i>p</i><0.001. For (E) TGCT, there were no patient samples with a stage IV diagnosis. (F) LAML staging was measured using the French-American-British (FAB) classifications.</p

Patients with high levels of <i>DNMT3B7</i> expression have lower survival rates than those with low expression levels.

<p>The median <i>DNMT3B7</i> expression for each individual tumor was determined to divide patients with that tumor into “high” (gray, dotted line) and “low” (black, solid line) expression groups. Kaplan-Meier curves were generated and statistical significance was determined for (A) CESC, <i>p</i> = 0.025; (B) KIRC, <i>p</i> = 0.009; (C) LAML, <i>p</i> = 0.035; (D) MESO, <i>p</i> = 0.013; (E) SARC, <i>p</i> = 0.003; and (F) SKCM, <i>p</i> = 0.003.</p